Dr. Reddy's

Dr. Reddy’s Laboratories has introduced a novel class of treatment in India for acid reflux, launching a Potassium-Competitive Acid Blocker (PCAB). This new therapy represents an advancement over conventional proton pump inhibitors (PPIs), promising faster onset of action, longer duration of relief, and improved patient outcomes. The launch underscores Dr. Reddy’s commitment to innovation in gastroenterology while addressing a widespread health concern that affects millions of Indians.

Dr. Reddy’s Laboratories reported a modest 1% year-on-year increase in consolidated net profit for the first quarter, reaching Rs. 1,410 crore. The pharmaceutical major saw its revenue grow by 10% during the same period, driven largely by its North America and emerging markets operations. Despite pricing pressure and regulatory headwinds in key geographies, the company maintained operational resilience through strategic launches and sustained product momentum. With a diversified global footprint and a focus on innovation, Dr.